4-1BB/TNFRSF9/CD137 Antibody (2356B) [Alexa Fluor™ Plus 488]

• Clone: 2356B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor Plus 488

4-1BB/TNFRSF9/CD137 Antibody (2356B) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects human 4‑1BB/TNFRSF9/CD137 in direct ELISAs.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for 4-1BB/TNFRSF9/CD137 Antibody (2356B) [Alexa Fluor™ Plus 488]

• 4-1BB ligand receptor
• 41BB
• 4-1BB
• CD137 antigen
• CD137
• CD137MGC2172
• CDw137
• FLJ43501
• ILA
• ILAhomolog of mouse 4-1BB
• induced by lymphocyte activation (ILA)
• interleukin-activated receptor, homolog of mouse Ly63
• receptor protein 4-1BB
• T cell antigen ILA
• T-cell antigen 4-1BB homolog
• T-cell antigen ILA
• TNFRSF9
• tumor necrosis factor receptor superfamily member 9
• tumor necrosis factor receptor superfamily, member 9

Background

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4⁺, CD8⁺, memory CD8⁺, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8⁺ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells (9, 10).
4-1BB activation enhances CD8⁺ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

1. Wang, C. et al. (2009) Immunol. Rev. 229:192.
2. Schwarz, H. et al. (1993) Gene 134:295.
3. Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
4. Wen, T. et al. (2002) J. Immunol. 168:4897.
5. Pulle, G. et al. (2006) J. Immunol. 176:2739.
6. Zheng, G. et al. (2004) J. Immunol. 173:2428.
7. Kim, D. et al. (2008) J. Immunol. 180:2062.
8. Lee, S. et al. (2008) Nat. Immunol. 9:917.
9. Choi, B.K. et al. (2009) J. Immunol. 182:4107.
10. Nishimoto, H. et al. (2005) Blood 106:4241.
11. Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
12. Lee, S. et al. (2005) J. Immunol. 174:6803.
13. Ma, B.Y. et al. (2005) Blood 106:2002.
14. Choi, B.K. et al. (2010) J. Immunol. 185:1404.
15. Kim, C. et al. (2011) Diabetes 60:3159.
16. Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
17. Salih, H.R. et al. (2001) J. Immunol. 167:4059.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.